Metropolis Healthcare Limited
Quick Take
- • Trading at 61.4× trailing earnings (38.4× forward)
- • Moderate ROE at 13.3%
- • Low leverage (D/E 0.15)
- • Modest dividend yield of 0.34%
- • Operating margin 17.5% · Net margin 11.8%
- • Profit growth +12.70% YoY · Beta 0.20
Latest quarter · Jun 2026
| ₹ Cr | Jun 2026 | QoQ | YoY |
|---|---|---|---|
| Revenue | 450 | +5.88% | +30.43% |
| Operating Profit | 116 | +0.00% | +68.12% |
| Net Profit | 57 | +11.76% | +96.55% |
| EPS (₹) | 2.73 | +10.98% | — |
Shareholding Pattern
| Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Promoters▼0.01 | 49.40% | 48.90% | 48.89% | 48.89% | 48.88% | 48.87% | 48.87% | 48.86% |
| FIIs▲0.60 | 16.73% | 15.29% | 12.83% | 12.52% | 11.69% | 10.77% | 10.43% | 11.03% |
| DIIs▼0.67 | 30.00% | 30.30% | 32.40% | 33.10% | 34.73% | 35.46% | 35.79% | 35.12% |
| Government | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public▲0.08 | 3.87% | 5.52% | 5.88% | 5.49% | 4.71% | 4.91% | 4.91% | 4.99% |
| No. of Shareholders | 48,572 | 49,293 | 50,015 | 47,846 | 46,670 | 48,488 | 49,175 | 50,636 |
* N
| Date | Party | Type | Side | Qty | Price |
|---|---|---|---|---|---|
| 11 Aug 26 | Aditya Birla Sun Life Mutual Fund | Block deal | BUY | 10,49,000 | ₹564.00 |
| 11 Aug 26 | Duru Shah Family Trust | Block deal | SELL | 10,50,000 | ₹564.00 |
| 11 Aug 26 | Icici Prudential Mutual Fund | Block deal | BUY | 5,25,500 | ₹564.00 |
| 11 Aug 26 | Metz Advisory Llp | Block deal | SELL | 10,50,000 | ₹564.00 |
| 11 Aug 26 | Morgan Stanley Asia Singapore Pte | Block deal | BUY | 5,25,500 | ₹564.00 |
| 11 Aug 26 | Aditya Birla Sun Life Mutual Fund | Bulk deal | BUY | 10,49,000 | ₹564.00 |
| 11 Aug 26 | Duru Shah Family Trust | Bulk deal | SELL | 10,50,000 | ₹564.00 |
| 11 Aug 26 | Metz Advisory Llp | Bulk deal | SELL | 10,50,000 | ₹564.00 |
| 16 Oct 25 | Goldman Sachs (Singapore) Pte.- Odi | Block deal | SELL | 55,000 | ₹1,944.00 |
| 16 Oct 25 | Goldman Sachs Bank Europese - Odi | Block deal | BUY | 55,000 | ₹1,944.00 |
About the company
From latest AR & concallMetropolis Healthcare Limited, together with its subsidiaries, provides pathology and related healthcare services in India and internationally. The company offers routine and specialised pathology tests; advanced diagnostics, including genetic, molecular, and cytogenetic testing; preventive healthcare packages and corporate wellness screening; clinical trial research, hospital lab management, and home collection services; radiology services, including X-ray, sonography and ECG; and next-generation sequencing services. It also provides diagnostic services for oncology, chronic and infectious diseases, gastroenterology, neurology, nephrology, and women and child health, as well as various health checkup and laboratory services. The company serves a range of customers, including direct-to-consumer diagnostics through patient service centers, mobile app, website, and home collection; partnerships with standalone labs, hospital chains, and diagnostic networks; and institutional clients, such as corporates, government bodies, and hospital lab management services. Metropolis Healthcare Limited was founded in 1980 and is headquartered in Mumbai, India.
